Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERtuzumab-trastuzumab Plus lEetrozoLe In Endocrine Sensitive Breast Cancer: a Phase II neoAdjuvant Study

NCT02411344 is registered in ClinicalTrials.gov with Istituto Oncologico Veneto IRCCS as lead sponsor.

NCT NCT02411344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02411344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERtuzumab-trastuzumab Plus lEetrozoLe In Endocrine Sensitive Breast Cancer: a Phase II neoAdjuvant Study
Lead sponsor
Istituto Oncologico Veneto IRCCS
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
January 12, 2018
Enrollment
64 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

endocrine sensitive her2+/hr+ breast cancer